论文部分内容阅读
肝内血管阻力处于神经体液控制下.已证明β_2肾上腺素能受体调节血窦容量.Mc-Cuskey发现给予去甲肾上腺素后,肝窦内皮细胞收缩;而给予β肾上腺素能受体兴奋剂异丙肾上腺素后则舒张.在硬化肝内纤维间隔和肝窦周围存在肌成纤维细胞(myofibroblasts).这种细胞收缩时,可使硬化肝内门脉血流阻力增加;作用于这些肌成纤维细胞的血管扩张剂则可减少肝内门脉血流的阻力.因此,在临床上为治疗门脉高压开辟了新的途径,即应用血管扩张药降低门脉压.目前认为,这类药物可用于两种不同情况.其一,用于急性食管曲张静脉破裂出血(EVB)时,作为血管收缩疗法的辅助治疗,以减少和避
Intrahepatic vascular resistance is under neurohumoral control, and β 2 adrenergic receptors have been shown to regulate sinusoidal capacity. Mc-Cuskey found that hepatic sinusoid endothelial cells contracted after administration of norepinephrine; whereas β-adrenergic receptor agonists When isoproterenol is dilated, there are myofibroblasts around the sclera and within the cirrhosis of the liver, and this contraction of the cells increases the resistance to flow in the hardened intrahepatic portal blood vessels; Fibrovascular vasodilator can reduce the intrahepatic portal blood flow resistance.Therefore, in the clinical treatment of portal hypertension has opened up a new way, that is, the use of vasodilators to reduce portal pressure.Currently, such drugs Can be used in two different situations: First, as an adjunct to vasoconstrictor therapy for acute esophageal variceal bleeding (EVB) to reduce and avoid